# Phase 0 Closure Evidence Package Plan V0.1 - OpenEMR IM Core

## AI-Assisted Solo-Owner Applicability

Separate reviewer records described by this plan remain future Phase 0 closure
evidence. They are not mandatory internal merge gates for work classified as
eligible by the AI-Assisted Solo-Owner Governance Policy V0.1.

The eligible-work Project Owner decision is AI-assisted and non-independent and
does not complete a closure package, close Phase 0, authorize a phase
transition, or satisfy an external qualified-human obligation.

## 1. Purpose

This document defines a planning-only structure for a future Phase 0 closure evidence package for the OpenEMR IM Core project.

This document identifies evidence categories, expected evidence sources, evidence review expectations, acceptance criteria, rejection criteria, and safety boundaries that must be considered before any future Phase 0 closure report may be prepared.

This document is a plan only.

It is not a completed evidence package.
It is not a Phase 0 closure report.
It does not claim Phase 0 closure.
It does not authorize runtime implementation, PHI use, real patient data use, AI/CDS operation, API/FHIR implementation, database migration, OpenEMR core behavior change, pilot use, production deployment, clinical use, clinical validation, regulatory compliance, cybersecurity certification, or production readiness.

## 2. Current Project Stage

OpenEMR IM Core remains in the following current stage:

- documentation-stage
- governance-stage
- planning-only
- pre-runtime
- pre-implementation
- pre-clinical-use

This document does not change the current project stage.

The evidence package described here is a future planning structure only and must not be interpreted as evidence that Phase 0 is closed or ready to close.

## 3. Scope of This Plan

This plan defines how future Phase 0 closure evidence may be organized.

It covers:

- evidence categories
- evidence source expectations
- evidence ownership
- evidence acceptance criteria
- evidence rejection criteria
- reviewer expectations
- traceability expectations
- gap linkage expectations
- documentation index linkage
- non-authorization boundaries
- post-review expectations

This plan does not create, approve, validate, or certify the evidence package.

## 4. Related Current-Stage Artifacts

This plan should be read together with:

- `custom/im-core/docs/roadmap/phase-0-closure-readiness-checklist-v0.1.md`
- `custom/im-core/docs/governance/phase-0-governance-closure-gap-summary-v0.1.md`
- `custom/im-core/docs/governance/formal-reviewer-approval-matrix-v0.1.md`
- `custom/im-core/docs/governance/formal-reviewer-approval-record-template-v0.1.md`
- `custom/im-core/docs/governance/reviewer-approval-workflow-sop-v0.1.md`
- `custom/im-core/docs/governance/human-accountability-raci-v0.1.md`
- `custom/im-core/docs/product/intended-use-scope-users-claims-v0.1.md`
- `custom/im-core/docs/requirements/requirements-management-plan-v0.1.md`
- `custom/im-core/docs/requirements/requirements-register-starter-v0.1.md`
- `custom/im-core/docs/requirements/requirements-traceability-population-starter-v0.1.md`
- `custom/im-core/docs/clinical-safety/clinical-safety-case-v0.1.md`
- `custom/im-core/docs/security/threat-model-and-data-governance-v0.1.md`
- `custom/im-core/docs/claims/commercial-claims-policy-and-claims-register-v0.1.md`
- `custom/im-core/docs/index/documentation-index-and-review-cadence-v0.1.md`

If this plan conflicts with a stricter safety, privacy, clinical safety, claims, regulatory, cybersecurity, lifecycle, or governance boundary, the stricter and safer interpretation prevails.

## 5. Evidence Package Planning Objective

The future Phase 0 closure evidence package, if prepared, should support a controlled decision about whether a future Phase 0 closure report may be considered.

The evidence package should help reviewers determine:

- whether required current-stage governance artifacts exist
- whether artifacts are indexed
- whether artifact status is current
- whether known gaps are documented
- whether closure no-go conditions remain unresolved
- whether reviewer approval expectations are defined
- whether claims boundaries remain conservative
- whether no PHI, runtime, AI/CDS, API/FHIR, database, or clinical-use transition has been introduced
- whether any closure claim would be premature

## 6. Evidence Categories

A future evidence package should organize evidence into the following categories:

| Evidence category | Purpose | Current-stage interpretation |
|---|---|---|
| Documentation inventory evidence | Shows which artifacts exist and where they are indexed. | Planning evidence only. |
| Governance boundary evidence | Shows current-stage limitations and prohibited claims. | Does not authorize implementation. |
| Intended-use and claims evidence | Shows planning-draft intended-use and claims boundaries. | Does not approve clinical use. |
| Reviewer approval evidence | Shows reviewer roles, workflow, and approval record structure. | Does not itself close Phase 0. |
| Gap evidence | Shows known remaining Phase 0 gaps. | Does not resolve gaps by itself. |
| Requirements evidence | Shows requirements planning status. | Not validated requirements evidence. |
| Traceability evidence | Shows traceability planning status. | Not complete verification evidence. |
| Risk evidence | Shows risk planning status. | Not implementation risk acceptance. |
| Clinical safety evidence | Shows clinical safety planning status. | Not clinical validation. |
| Privacy and security evidence | Shows privacy/security planning boundaries. | Not privacy compliance or cybersecurity certification. |
| Validation and verification evidence | Shows current V&V planning status. | Not runtime validation. |
| Release-readiness evidence | Shows whether release readiness is prohibited or deferred. | Not release approval. |
| Post-merge verification evidence | Shows PR-level merge and index verification. | Not clinical or production readiness. |

## 7. Minimum Evidence Items Before Future Closure Report Consideration

Before any future Phase 0 closure report is considered, the evidence package should include at least:

| Evidence ID | Evidence item | Expected source |
|---|---|---|
| EVID-P0-001 | Current documentation index entry coverage | Documentation index |
| EVID-P0-002 | Phase 0 closure readiness checklist | Phase 0 readiness checklist |
| EVID-P0-003 | Phase 0 governance closure gap summary | Phase 0 gap summary |
| EVID-P0-004 | Current intended-use, scope, users, and claims boundary | Product intended-use / claims document |
| EVID-P0-005 | Human accountability and ownership evidence | Human accountability RACI |
| EVID-P0-006 | Formal reviewer approval matrix | Reviewer approval matrix |
| EVID-P0-007 | Formal reviewer approval record template | Reviewer approval record template |
| EVID-P0-008 | Reviewer approval workflow SOP | Reviewer approval workflow SOP |
| EVID-P0-009 | Requirements planning status | Requirements management plan and starter register |
| EVID-P0-010 | Traceability planning status | Traceability population starter |
| EVID-P0-011 | Clinical safety planning status | Clinical safety case |
| EVID-P0-012 | Privacy and security planning status | Threat model and data governance documents |
| EVID-P0-013 | Claims control status | Commercial claims policy and claims register |
| EVID-P0-014 | Current open gaps | Gap summary and readiness checklist |
| EVID-P0-015 | Post-merge verification records for relevant PRs | PR audit trail and local verification outputs |

## 8. Evidence Acceptance Criteria

Evidence should be accepted into a future Phase 0 evidence package only if it meets all applicable criteria:

- artifact path is clear
- artifact is present on `master`
- artifact is listed in the documentation index when applicable
- artifact status is clear
- artifact scope is current-stage appropriate
- artifact does not contain PHI, secrets, credentials, or real patient data
- artifact does not introduce runtime implementation
- artifact does not introduce AI/CDS operation
- artifact does not introduce API/FHIR implementation
- artifact does not introduce SQL/database migration
- artifact does not introduce OpenEMR core behavior changes
- artifact does not claim clinical validation
- artifact does not claim production readiness
- artifact does not claim regulatory compliance
- artifact does not claim cybersecurity certification
- artifact does not claim Phase 0 closure unless part of a separately approved future closure report
- artifact has a clear owner or accountable review role
- artifact has been merged through controlled PR workflow

## 9. Evidence Rejection Criteria

Evidence should be rejected or deferred if any of the following apply:

- file path is unclear
- artifact is missing from `master`
- artifact is stale or contradicted by newer documents
- artifact is not indexed when index coverage is required
- artifact changes intended use without controlled approval
- artifact changes scope, users, or claims without controlled approval
- artifact introduces unsupported readiness claims
- artifact introduces PHI, secrets, credentials, or real patient data
- artifact implies runtime behavior without authorization
- artifact implies clinical use, pilot use, production use, or deployment readiness
- artifact implies validation, regulatory compliance, or cybersecurity certification without evidence
- artifact creates duplicate source-of-truth conflict
- artifact lacks clear ownership or review responsibility
- artifact is not linked to the relevant gap, risk, requirement, or review context when linkage is needed

## 10. Evidence Ownership Expectations

Each evidence item should have a clear accountable owner.

Possible owner roles include:

- Governance Owner
- Documentation Owner
- Technical Owner
- Clinical Safety Owner
- Risk Owner
- Evidence Reviewer
- Privacy-Security Owner
- Regulatory Reviewer
- AI Governance Owner
- Operations Owner
- Release Owner

Ownership does not imply clinical authorization, regulatory approval, cybersecurity certification, or production approval.

## 11. Reviewer Expectations

A future Phase 0 evidence package should be reviewed using the formal reviewer approval governance artifacts.

Reviewer review should consider:

- completeness of evidence
- correctness of artifact references
- consistency with current-stage boundaries
- unresolved gaps
- unresolved risks
- claims-control compliance
- source-of-truth conflicts
- evidence freshness
- whether any closure claim would be premature

Formal approval records should be completed only when required by the reviewer approval workflow SOP.

## 12. Traceability Expectations

Evidence items should be traceable to:

- current governance artifacts
- documentation index entries
- known Phase 0 gaps
- reviewer roles
- current-stage boundaries
- future closure report prerequisites

Traceability in this plan is planning-level only.

It does not represent complete verification traceability or validated lifecycle traceability.

## 13. Relationship to Gap Summary

The Phase 0 Governance Closure Gap Summary V0.1 identifies remaining gaps before future Phase 0 closure may be considered.

This evidence package plan defines how evidence may be organized to support review of those gaps.

This plan does not resolve the gaps by itself.

This plan does not claim that any gap has been closed.

## 14. Relationship to Future Phase 0 Closure Report

A future Phase 0 closure report, if ever prepared, should be separate from this plan.

This plan may support future closure report preparation only by defining expected evidence organization.

This plan must not be cited as proof that:

- Phase 0 is closed
- closure evidence is complete
- governance foundation is fully approved
- runtime work is authorized
- clinical use is authorized
- production deployment is authorized
- validation is complete
- regulatory compliance is established
- cybersecurity certification is established

## 15. Explicit Non-Authorization Statement

This document does not authorize:

- Phase 0 closure
- runtime implementation
- implementation planning beyond documentation-stage governance
- PHI use
- real patient data use
- AI/CDS runtime operation
- prompt execution
- model integration
- API/FHIR implementation
- SQL/database migration
- OpenEMR core behavior change
- pilot use
- demo use with real data
- production deployment
- clinical use
- autonomous diagnosis
- autonomous treatment
- autonomous prescribing
- autonomous triage
- clinical validation
- regulatory compliance claim
- cybersecurity certification claim
- production-readiness claim

## 16. Risk Controls for Misinterpretation

| Risk | Potential harm | Control |
|---|---|---|
| Evidence plan mistaken for completed evidence package | Premature closure decision | Explicit plan-only language. |
| Evidence package mistaken for closure report | Premature Phase 0 closure claim | Separate future closure report required. |
| Planning evidence mistaken for validation evidence | Unsupported readiness claim | No validation or clinical-use language. |
| Reviewer records mistaken for regulatory approval | Unsupported compliance claim | Current-stage reviewer limitation. |
| Security planning mistaken for certification | Unsupported cybersecurity claim | Certification claims prohibited. |
| Privacy planning mistaken for PHI authorization | Privacy risk | No-PHI boundary. |
| Governance evidence mistaken for runtime readiness | Unsafe implementation expectation | Pre-runtime boundary. |

## 17. Future Evidence Package Assembly Steps

If a future evidence package is assembled, it should follow this sequence:

1. Confirm current branch is up to date with `master`.
2. Confirm documentation index is current.
3. Identify evidence artifacts by path.
4. Map evidence artifacts to known Phase 0 gaps.
5. Identify missing evidence.
6. Identify stale or conflicting evidence.
7. Apply evidence acceptance and rejection criteria.
8. Request required reviewer review.
9. Complete formal reviewer approval records where required.
10. Document unresolved gaps.
11. Confirm no prohibited claims are introduced.
12. Prepare a separate future closure report only if evidence and governance approvals justify consideration.

## 18. Post-Merge Verification Expectations

After this plan is merged, verification should confirm:

- this file exists on `master`
- the documentation index includes this artifact
- the PR is merged through controlled review
- GitHub checks completed successfully
- no unrelated files were changed
- local working tree is clean
- no Phase 0 closure claim was introduced
- no completed evidence package claim was introduced

## 19. Maintenance and Review

This plan should be reviewed if:

- Phase 0 closure gaps change
- closure readiness criteria change
- evidence requirements change
- reviewer approval governance changes
- documentation index structure changes
- intended-use, scope, users, or claims boundaries change
- requirements, risk, validation, clinical safety, privacy, security, or release-readiness artifacts change materially
- any future runtime, pilot, deployment, or clinical-use planning is proposed

Updates should be made through a controlled documentation-only PR.

## 20. Version and Ownership

| Field | Value |
|---|---|
| Document | Phase 0 Closure Evidence Package Plan V0.1 |
| Project | OpenEMR IM Core |
| Status | Approved for current-stage planning after merge |
| Stage | Documentation-stage / governance-stage / planning-only |
| Artifact type | Evidence package planning document |
| Completed evidence package | No |
| Phase 0 closure report | No |
| Phase 0 closure claim | No |
| Runtime impact | None |
| Clinical-use authorization | None |
| PHI authorization | None |
| AI/CDS runtime authorization | None |
| Production-readiness claim | None |
| Owner | Governance Owner / Documentation Owner |
